FDA approves AstraZeneca’s tremelimumab for liver cancer
ADC评论
October 24, 2022
On October 21, the FDA’s official website showed that AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab (temslimumab) was approved by the FDA for listing, and the approved
